Disassociation of histone deacetylase-3 from normal huntingtin underlies mutant huntingtin neurotoxicity

Journal of Neuroscience

Volumn 33, Issue 29, 2013, Pages 11833-11838

  Bardai, Farah H ^a   Verma, Pragya ^a   Smith, Chad ^a   Rawat, Varun ^a   Wang, Lulu ^a   D'Mello, Santosh R ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; HISTONE DEACETYLASE 3; HUNTINGTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IMMUNOPRECIPITATION; LOSS OF FUNCTION MUTATION; MOUSE; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; HISTONE DEACETYLASES; HUNTINGTON DISEASE; MICE; MUTATION; NEURONS;

EID: 84880422675     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.5831-12.2013     Document Type: Article

References (29)

1. Aiken CT, Steffan JS, Guerrero CM, Khashwji H, Lukacsovich T, Simmons D, Purcell JM, Menhaji K, Zhu YZ, Green K, Laferla F, Huang L, Thompson LM, Marsh JL (2009) Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J Biol Chem 284:29427-29436. CrossRef Medline
2. Bardai FH, D'Mello SR (2011) Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3. J Neurosci 31:1746-1751. CrossRef Medline
3. Bardai FH, Price V, Zaayman M, Wang L, D'Mello SR (2012) Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death. J Biol Chem 287:35444-35453. CrossRef Medline
4. Bates EA, Victor M, Jones AK, Shi Y, Hart AC (2006) Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J Neurosci 26:2830-2838. CrossRef Medline
5. Carmichael J, Sugars KL, Bao YP, Rubinsztein DC (2002) Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington'S disease mutation. J Biol Chem 277:33791-33798. CrossRef Medline
6. Cha JH (2000) Transcriptional dysregulation in huntington'S disease. Trends Neurosci 23:387-392. CrossRef Medline
7. Crook ZR, Housman D (2011) Huntington'S disease: can mice lead the way to treatment? Neuron [Erratum (2011) 69:1038] 69:423-435. CrossRef Medline
8. Dastidar SG, Landrieu PM, D'Mello SR (2011) FoxG1 promotes the survival of postmitotic neurons. J Neurosci 31:402-413. CrossRef Medline
9. D'Mello SR, Galli C, Ciotti T, Calissano P (1993) Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and cAMP. Proc Natl Acad Sci U S A 90: 10989-10993. CrossRef Medline
10. Dragatsis I, Levine MS, Zeitlin S (2000) Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 26:300-306. CrossRef Medline
11. Ho LW, Brown R, Maxwell M, Wyttenbach A, Rubinsztein DC (2001) Wild type huntingtin reduces the cellular toxicity of mutant huntingtin in mammalian cell models of huntington'S disease. J Med Genet 38:450-452. CrossRef Medline
12. Humbert S, Bryson EA, Cordelieres FP, Connors NC, Datta SR, Finkbeiner S, Greenberg ME, Saudou F (2002) The IGF-1/akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by akt. Dev Cell 2:831-837. CrossRef Medline
13. Jeong H, Then F, Melia TJ Jr, Mazzulli JR, Cui L, Savas JN, Voisine C, Paganetti P, Tanese N, Hart AC, Yamamoto A, Krainc D (2009) Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 137: 60-72. CrossRef Medline
14. Jia H, Pallos J, Jacques V, Lau A, Tang B, Cooper A, Syed A, Purcell J, Chen Y, Sharma S, Sangrey GR, Darnell SB, Plasterer H, Sadri-Vakili G, Gottesfeld JM, Thompson LM, Rusche JR, Marsh JL, Thomas EA (2012) Histone deacetylase (HDAC) inhibitors targetingHDAC3andHDAC1ameliorate polyglutamine-elicited phenotypes in model systems of huntington's disease. Neurobiol Dis 46:351-361. CrossRef Medline
15. Leavitt BR, Guttman JA, Hodgson JG, Kimel GH, Singaraja R, Vogl AW, Hayden MR (2001) Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet 68:313-324. CrossRef Medline
16. Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK, Wellington CL, Raymond LA, Hayden MR (2006) Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem 96:1121-1129. CrossRef Medline
17. Majdzadeh N, Wang L, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR (2008) HDAC4 inhibits cell-cycle progression and protects neurons from cell death. Dev Neurobiol 68:1076-1092. CrossRef Medline
18. Moumné L, Campbell K, Howland D, Ouyang Y, Bates GP (2012) Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of huntington's disease. PLoS One 7:e31080. CrossRef Medline
19. Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J, Borowski A, Marth JD, Phillips AG, Hayden MR (1995) Targeted disruption of the huntington'S disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81:811-823. CrossRef Medline
20. Rangone H, Pardo R, Colin E, Girault JA, Saudou F, Humbert S (2005) Phosphorylation of arfaptin 2 at Ser260 by akt inhibits PolyQ-huntingtininduced toxicity by rescuing proteasome impairment. J Biol Chem 280: 22021-22028. CrossRef Medline
21. Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, Sciorati C, Clementi E, Hackam A, Hayden MR, Li Y, Cooper JK, Ross CA, Govoni S, Vincenz C, Cattaneo E (2000) Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 20:3705-3713. Medline
22. Ross CA, Tabrizi SJ (2011) Huntington'S disease: From molecular pathogenesis to clinical treatment. Lancet Neurol 10:83-98. CrossRef Medline
23. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, Kazantsev A, Schmidt E, Zhu YZ, Greenwald M, Kurokawa R, Housman DE, Jackson GR, Marsh JL, Thompson LM (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739-743. CrossRef Medline
24. Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, Burnett R, Gao F, Fitzgerald KM, Borok JF, Herman D, Geschwind DH, Gottesfeld JM (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in huntington'S disease transgenic mice. Proc Natl Acad Sci U S A 105:15564-15569. CrossRef Medline
25. Valencia A, Sapp E, Reeves PB, Alexander J, Masso N, Li X, Kegel KB, DiFiglia M (2012) Reagents that block neuronal death from huntington'S disease also curb oxidative stress. Neuroreport 23:10-15. CrossRef Medline
26. Van Raamsdonk JM, Pearson J, Rogers DA, Bissada N, Vogl AW, Hayden MR, Leavitt BR (2005) Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of huntington disease. Hum Mol Genet 14:1379-1392. CrossRef Medline
27. Zhang Y, Li M, Drozda M, Chen M, Ren S, Mejia Sanchez RO, Leavitt BR, Cattaneo E, Ferrante RJ, Hayden MR, Friedlander RM (2003) Depletion of wild-type huntingtin in mouse models of neurologic diseases. J Neurochem 87:101-106. CrossRef Medline
28. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington'S disease. Science 293:493-498. CrossRef Medline
29. Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in huntington'S disease. Physiol Rev 90:905-981. CrossRef Medline